

Eric Hachulla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1164618/publications.pdf>

Version: 2024-02-01

467
papers

44,170
citations

1536

106
h-index

3034

188
g-index

508
all docs

508
docs citations

508
times ranked

28579
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary Arterial Hypertension in France. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1023-1030.	5.6	1,736
2	Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era. Circulation, 2010, 122, 156-163.	1.6	1,264
3	Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 330-340.	27.0	1,120
4	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the Rheumatic Diseases, 2010, 69, 1809-1815.	0.9	1,017
5	Tadalafil Therapy for Pulmonary Arterial Hypertension. Circulation, 2009, 119, 2894-2903.	1.6	956
6	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.9	794
7	Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 2522-2533.	27.0	790
8	Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. New England Journal of Medicine, 2009, 360, 2416-2425.	27.0	754
9	EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2010, 69, 1103-1109.	0.9	734
10	Eosinophilic granulomatosis with polyangiitis (Churg-H Strauss): Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis and Rheumatism, 2013, 65, 270-281.	6.7	670
11	Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis and Rheumatism, 2005, 52, 3792-3800.	6.7	656
12	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Annals of the Rheumatic Diseases, 2015, 74, 1011-1018.	0.9	610
13	Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. European Respiratory Journal, 2010, 36, 549-555.	6.7	582
14	Neurologic Manifestations in Primary Sjögren Syndrome. Medicine (United States), 2004, 83, 280-291.	1.0	536
15	Clinical picture and treatment of 2212 patients with common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2014, 134, 116-126.e11.	2.9	512
16	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases, 2021, 80, 930-942.	0.9	496
17	Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. Arthritis and Rheumatism, 2010, 62, 616-626.	6.7	483
18	Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1897-1905.	0.9	410

#	ARTICLE	IF	CITATIONS
19	Infections in 252 Patients with Common Variable Immunodeficiency. <i>Clinical Infectious Diseases</i> , 2008, 46, 1547-1554.	5.8	394
20	EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 968-972.	0.9	383
21	Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS). <i>Arthritis and Rheumatism</i> , 2004, 50, 1270-1276.	6.7	368
22	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010, 62, 2458-2466.	6.7	352
23	Treatment of Primary Sjögren Syndrome With Rituximab. <i>Annals of Internal Medicine</i> , 2014, 160, 233-242.	3.9	325
24	Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. <i>JAMA Neurology</i> , 2018, 75, 1528.	9.0	301
25	Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival. <i>Arthritis and Rheumatism</i> , 2011, 63, 3522-3530.	6.7	291
26	Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1355-1360.	0.9	275
27	Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010, 62, 2625-2632.	6.7	266
28	Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1428-1432.	0.9	262
29	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. <i>Journal of Medical Genetics</i> , 2017, 54, 288-296.	3.2	262
30	Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 351-357.	0.9	261
31	Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. <i>Lancet, The</i> , 2009, 374, 1986-1996.	13.7	246
32	Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. <i>Autoimmunity Reviews</i> , 2012, 12, 210-217.	5.8	233
33	Efficacy and safety of atacept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2006-2015.	0.9	231
34	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102458.	5.8	231
35	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015, 1, e000022-e000022.	3.8	229
36	Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1878-1884.	0.9	227

#	ARTICLE	IF	CITATIONS
37	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 382-389.	0.9	225
38	Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1388-1393.e8.	2.9	222
39	Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 218-221.	0.9	214
40	COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e419-e426.	3.9	211
41	Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. <i>Blood</i> , 2014, 124, 1119-1126.	1.4	208
42	Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis. <i>PLoS Genetics</i> , 2011, 7, e1002091.	3.5	205
43	Survival and Prognostic Factors in Systemic Sclerosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2412-2423.	6.7	205
44	Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2074-2081.	0.9	204
45	Mevalonate Kinase Deficiency: A Survey of 50 Patients. <i>Pediatrics</i> , 2011, 128, e152-e159.	2.1	195
46	Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1026-1031.	0.9	193
47	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 859-866.	0.9	193
48	Late-Onset Combined Immune Deficiency: A Subset of Common Variable Immunodeficiency with Severe T Cell Defect. <i>Clinical Infectious Diseases</i> , 2009, 49, 1329-1338.	5.8	192
49	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 362-375.	5.6	189
50	Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2095-2102.	0.9	182
51	Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212608.	0.9	181
52	Association between the <i>IRF5</i> rs2004640 functional polymorphism and systemic sclerosis: A new perspective for pulmonary fibrosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 225-233.	6.7	180
53	The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. <i>Arthritis and Rheumatism</i> , 2009, 60, 1831-1839.	6.7	179
54	Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. <i>Journal of Autoimmunity</i> , 2015, 62, 67-74.	6.5	178

#	ARTICLE	IF	CITATIONS
55	Recommendations for Screening and Detection of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatism</i> , 2013, 65, 3194-3201.	6.7	175
56	Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. <i>PLoS ONE</i> , 2017, 12, e0183844.	2.5	174
57	Association of an <i>IRF5</i> gene functional polymorphism with Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2007, 56, 3989-3994.	6.7	173
58	Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 175.	7.4	171
59	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2087-2093.	0.9	168
60	Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 295-304.	6.7	163
61	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. <i>European Heart Journal</i> , 2017, 38, 2649-2662.	2.2	163
62	Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. <i>Journal of Rheumatology</i> , 2010, 37, 1488-1501.	2.0	161
63	Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis. <i>Circulation</i> , 2017, 136, 1114-1122.	1.6	161
64	Pulmonary Arterial Hypertension: A Rare Complication of Primary Sjögren Syndrome. <i>Medicine (United States)</i> , 2014, 93, 372-382.	1.0	160
65	Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1786-1792.	0.9	160
66	Kikuchi-Fujimoto Disease. <i>Medicine (United States)</i> , 2014, 93, 372-382.	1.0	160
67	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 219-227.	0.9	160
68	Influence of Age on Characteristics of Polymyositis and Dermatomyositis in Adults. <i>Medicine (United States)</i> , 2014, 93, 372-382.	1.0	159
69	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. <i>PLoS ONE</i> , 2016, 11, e0163894.	2.5	158
70	Downregulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon β mimetic. <i>Arthritis and Rheumatism</i> , 2013, 65, 447-456.	6.7	155
71	Opportunistic infections in polymyositis and dermatomyositis. <i>Arthritis and Rheumatism</i> , 2005, 53, 155-165.	6.7	154
72	B-Cell and T-Cell Phenotypes in COVID Patients Correlate with the Clinical Phenotype of the Disease. <i>Journal of Clinical Immunology</i> , 2010, 30, 746-755.	3.8	150

#	ARTICLE	IF	CITATIONS
73	Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. <i>Rheumatology</i> , 2008, 48, 304-308.	1.9	148
74	Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. <i>Journal of Rheumatology</i> , 2007, 34, 2423-30.	2.0	148
75	Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. <i>Rheumatology</i> , 2012, 51, 460-467.	1.9	147
76	Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren's Syndrome. Data at Enrollment in the Prospective ASSESS Cohort. <i>PLoS ONE</i> , 2013, 8, e59868.	2.5	147
77	Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 495-499.	0.9	146
78	Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 977-985.	5.6	146
79	Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. <i>Annals of Neurology</i> , 2015, 78, 901-916.	5.3	143
80	Diagnosis and Classification of Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 40, 78-83.	6.5	142
81	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 979-987.	0.9	142
82	Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. <i>Rheumatology</i> , 2015, 54, 1008-1016.	1.9	141
83	<i>STAT4</i> is a genetic risk factor for systemic sclerosis having additive effects with <i>IRF5</i> on disease susceptibility and related pulmonary fibrosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2472-2479.	6.7	139
84	The French national registry of primary immunodeficiency diseases. <i>Clinical Immunology</i> , 2010, 135, 264-272.	3.2	137
85	The Clinical Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data From a French Nationwide Study of Fifty-seven Patients. <i>Arthritis and Rheumatology</i> , 2015, 67, 527-534.	5.6	136
86	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.9	132
87	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1042-1050.	0.9	132
88	Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. <i>Arthritis and Rheumatology</i> , 2016, 68, 1522-1530.	5.6	131
89	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 695-709.	0.9	130
90	Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 382-389.e1.	2.9	128

#	ARTICLE	IF	CITATIONS
91	Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1940-1946.	0.9	128
92	High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. <i>Journal of Rheumatology</i> , 2006, 33, 1789-801.	2.0	126
93	Granulomatous Disease in COVID: Retrospective Analysis of Clinical Characteristics and Treatment Efficacy in a Cohort of 59 Patients. <i>Journal of Clinical Immunology</i> , 2013, 33, 84-95.	3.8	125
94	High-dose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome. <i>Critical Care Medicine</i> , 2008, 36, 2184-2187.	0.9	124
95	Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. <i>Medicine (United States)</i> , 2014, 93, 340-349.	1.0	122
96	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2527-2539.	5.6	122
97	Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. <i>Autoimmunity Reviews</i> , 2015, 14, 1154-1160.	5.8	121
98	Association of the <i>TNFAIP3</i> rs5029939 variant with systemic sclerosis in the European Caucasian population. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1958-1964.	0.9	120
99	Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 2176-2184.	5.6	118
100	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. <i>Chest</i> , 2009, 136, 1211-1219.	0.8	117
101	Autoimmunity in common variable immunodeficiency: Correlation with lymphocyte phenotype in the French DEFI study. <i>Journal of Autoimmunity</i> , 2011, 36, 25-32.	6.5	117
102	Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 19.	2.7	117
103	Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Annals of Internal Medicine</i> , 2020, 173, 179-187.	3.9	116
104	Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: A series of 73 patients. <i>Arthritis Care and Research</i> , 2010, 62, 1748-1755.	3.4	115
105	Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis—Results from the International Scleroderma Renal Crisis Survey. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 666-672.	3.4	115
106	Interstitial Lung Disease in Anti-Jo-1 Patients With Antisynthetase Syndrome. <i>Arthritis Care and Research</i> , 2013, 65, 800-808.	3.4	114
107	Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. <i>Journal of Autoimmunity</i> , 2017, 80, 10-27.	6.5	114
108	Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. <i>Journal of Rheumatology</i> , 2002, 29, 75-83.	2.0	114

#	ARTICLE	IF	CITATIONS
109	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1009-1015.	0.9	112
110	Digital ulcers predict a worse disease course in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 681-686.	0.9	111
111	Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. <i>European Respiratory Journal</i> , 2013, 42, 1271-1282.	6.7	108
112	Infectious Complications in Polymyositis and Dermatomyositis: A Series of 279 Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 48-60.	3.4	107
113	Treatment of Systemic Sclerosis Complications: What to Use When First-Line Treatment Failsâ€”A Consensus of Systemic Sclerosis Experts. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 42-55.	3.4	107
114	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.9	107
115	Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. <i>Arthritis Research and Therapy</i> , 2011, 13, R202.	3.5	106
116	<i>BANK1</i> is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with <i>IRF5</i> and <i>STAT4</i> . <i>Arthritis and Rheumatism</i> , 2009, 60, 3447-3454.	6.7	105
117	The CCGGC insertion/deletion polymorphism of the <i>IRF5</i> promoter is a strong risk factor for primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2009, 60, 1991-1997.	6.7	104
118	Immunological profile in primary Sjögren syndrome. <i>Autoimmunity Reviews</i> , 2010, 9, 595-599.	5.8	103
119	Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjögren's syndrome. <i>Blood</i> , 2013, 122, 4068-4076.	1.4	103
120	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. <i>Microvascular Research</i> , 2013, 89, 122-128.	2.5	101
121	Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2016, 68, 690-701.	5.6	101
122	Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. <i>Arthritis and Rheumatism</i> , 2006, 54, 1697-1700.	6.7	100
123	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. <i>Thorax</i> , 2014, 69, 436-444.	5.6	100
124	Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. <i>Journal of Rheumatology</i> , 2008, 35, 1064-72.	2.0	99
125	Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. <i>Arthritis and Rheumatism</i> , 2009, 61, 108-118.	6.7	98
126	Pulmonary hypertension in systemic sclerosis: different phenotypes. <i>European Respiratory Review</i> , 2017, 26, 170056.	7.1	97

#	ARTICLE	IF	CITATIONS
127	Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. a prospective clinical and immunohistologic study in 59 patients. <i>Arthritis and Rheumatism</i> , 1993, 36, 691-697.	6.7	96
128	Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 718-721.	0.9	96
129	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1124-1131.	0.9	96
130	Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 632-643.	0.6	95
131	Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers. <i>Arthritis Care and Research</i> , 2011, 63, 277-285.	3.4	94
132	Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: A french multicenter study. <i>Autoimmunity Reviews</i> , 2014, 13, 1035-1041.	5.8	94
133	MR Imaging Findings in Hands in Early Rheumatoid Arthritis: Comparison with Those in Systemic Lupus Erythematosus and Primary Sjögren Syndrome. <i>Radiology</i> , 2005, 236, 593-600.	7.3	93
134	Articular manifestations in primary Sjogren's syndrome: clinical significance and prognosis of 188 patients. <i>Rheumatology</i> , 2010, 49, 1164-1172.	1.9	93
135	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 103-109.	0.9	93
136	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. <i>Journal of Rheumatology</i> , 2017, 44, 639-647.	2.0	93
137	Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalite 2005 survey, ANRS) Tj ETQq1 1 0.784314 rgBT /Ozrlock 10	1.4	93
138	Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. <i>British Journal of Dermatology</i> , 2012, 167, 1138-1144.	1.5	91
139	Hydroxychloroquine-Induced Pigmentation in Patients With Systemic Lupus Erythematosus. <i>JAMA Dermatology</i> , 2013, 149, 935.	4.1	91
140	Systemic sclerosis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000782.	3.8	91
141	Clinical Characteristics and Survival in Systemic Sclerosis-Related Pulmonary Hypertension Associated With Interstitial Lung Disease. <i>Chest</i> , 2011, 140, 1016-1024.	0.8	89
142	Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort. <i>RMD Open</i> , 2016, 2, e000179.	3.8	88
143	A descriptive and prognostic study of systemic sclerosis-associated myopathies. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1474-1477.	0.9	87
144	Clinical Features of Scleroderma Patients With or Without Prior or Current Ischemic Digital Ulcers: Post-Hoc Analysis of a Nationwide Multicenter Cohort (ItinAIR-Sclerodermie). <i>Journal of Rheumatology</i> , 2009, 36, 1470-1476.	2.0	86

#	ARTICLE	IF	CITATIONS
145	Lupus Anticoagulant-Hypoprothrombinemia Syndrome. <i>Medicine (United States)</i> , 2012, 91, 251-260.	1.0	85
146	Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti-Synthetase Auto-Antibodies: An Open-Label, Phase II Trial. <i>PLoS ONE</i> , 2015, 10, e0133702.	2.5	84
147	Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. <i>Journal of Rheumatology</i> , 2007, 34, 1005-11.	2.0	84
148	NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 668-674.	0.9	83
149	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.9	82
150	¹⁸ F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis. <i>Medicine (United States)</i> , 2016, 95, e3851.	1.0	80
151	Clinical and Morphologic Spectrum of Renal Involvement in Patients With Mixed Cryoglobulinemia Without Evidence of Hepatitis C Virus Infection. <i>Medicine (United States)</i> , 2009, 88, 341-348.	1.0	79
152	Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody. <i>British Journal of Dermatology</i> , 2010, 162, 337-344.	1.5	78
153	Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies. <i>American Journal of Pathology</i> , 2016, 186, 691-700.	3.8	78
154	Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1150-1158.	0.9	77
155	Active Immunological Profile Is Associated with Systemic Sjögren's Syndrome. <i>Journal of Clinical Immunology</i> , 2011, 31, 840-847.	3.8	76
156	Prevalence of Anti-RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2014, 66, 407-417.	5.6	76
157	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e85-e94.	3.9	76
158	Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. <i>Rheumatology</i> , 2010, 49, 972-976.	1.9	75
159	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	5.6	75
160	Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. <i>Autoimmunity Reviews</i> , 2018, 17, 582-587.	5.8	74
161	STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signaling. <i>Genes and Immunity</i> , 2010, 11, 432-438.	4.1	71
162	The Relapsing Polychondritis Disease Activity Index: Development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , 2012, 12, 204-209.	5.8	71

#	ARTICLE	IF	CITATIONS
163	European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: A Complete Picture of Primary Sjögren's Syndrome Patients. <i>Arthritis Care and Research</i> , 2013, 65, 1358-1364.	3.4	71
164	Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) 2010 survey. <i>HIV Medicine</i> , 2015, 16, 230-239.	2.2	71
165	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 618-625.	0.9	71
166	Recommendations for the care of oral involvement in patients with systemic sclerosis. <i>Arthritis Care and Research</i> , 2011, 63, 1126-1133.	3.4	68
167	Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1743-1748.	0.9	68
168	Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 2016, 67, 102-110.	6.5	68
169	Development of the autoinflammatory disease damage index (ADDI). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 821-830.	0.9	68
170	Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. <i>PLoS ONE</i> , 2017, 12, e0181692.	2.5	68
171	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. <i>Chest</i> , 2018, 153, 143-151.	0.8	68
172	Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. <i>Arthritis Care and Research</i> , 2010, 62, 551-558.	3.4	66
173	Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome. <i>European Journal of Internal Medicine</i> , 2013, 24, 474-479.	2.2	66
174	Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000793.	3.8	66
175	TNF alpha antagonist therapy and safety monitoring. <i>Joint Bone Spine</i> , 2011, 78, 15-185.	1.6	65
176	Takayasu Arteritis and Pregnancy. <i>Arthritis and Rheumatology</i> , 2015, 67, 3262-3269.	5.6	65
177	Ophthalmic manifestations in IgG4-related disease. <i>Medicine (United States)</i> , 2017, 96, e6205.	1.0	65
178	Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial. <i>Arthritis Care and Research</i> , 2017, 69, 528-535.	3.4	65
179	Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 498-505.	1.1	64
180	Diagnostic tools for amyloidosis. <i>Joint Bone Spine</i> , 2002, 69, 538-545.	1.6	63

#	ARTICLE	IF	CITATIONS
181	The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). <i>Journal of Inherited Metabolic Disease</i> , 2010, 33, 331-338.	3.6	63
182	Brief Report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the <i>TNFAIP3</i> locus as a risk factor for polyautoimmunity. <i>Arthritis and Rheumatism</i> , 2012, 64, 2746-2752.	6.7	63
183	Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. <i>Rheumatology</i> , 2011, 50, 1440-1444.	1.9	62
184	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. <i>Presse Medicale</i> , 2013, 42, 1317-1330.	1.9	62
185	Chronic histiocytic intervillositis: Outcome, associated diseases and treatment in a multicenter prospective study. <i>Autoimmunity</i> , 2015, 48, 40-45.	2.6	62
186	Blau Syndrome – Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series. <i>American Journal of Ophthalmology</i> , 2018, 187, 158-166.	3.3	62
187	Pulmonary manifestations of Sjögren's syndrome. <i>Presse Medicale</i> , 2011, 40, e71-e86.	1.9	61
188	Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: A national multicentric retrospective study. <i>Arthritis Care and Research</i> , 2011, 63, 1339-1344.	3.4	61
189	Overall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients. <i>Journal of Autoimmunity</i> , 2019, 96, 35-39.	6.5	61
190	Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 329-338.	0.9	61
191	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018, 52, 1800678.	6.7	60
192	Prognosis Assessment of Cardiac Involvement in Systemic AL Amyloidosis by Magnetic Resonance Imaging. <i>American Journal of Medicine</i> , 2010, 123, 864-868.	1.5	59
193	Fabry disease – The New Great Imposter™: results of the French Observatoire in Internal Medicine Departments (FIMeD). <i>Clinical Genetics</i> , 2012, 81, 571-577.	2.0	59
194	Ischemic Digital Ulcers Affect Hand Disability and Pain in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2014, 41, 1317-1323.	2.0	58
195	Altered B lymphocyte homeostasis and functions in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2018, 17, 244-255.	5.8	58
196	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1945-1950.	0.9	57
197	Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: Association with the functional IRAK1 196Phe/532Ser haplotype. <i>Arthritis and Rheumatism</i> , 2011, 63, 3979-3987.	6.7	56
198	Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. <i>Rheumatology</i> , 2011, 50, 2283-2289.	1.9	56

#	ARTICLE	IF	CITATIONS
199	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1285-1292.	0.9	56
200	The Clinical Picture of Severe Systemic Capillary-Leak Syndrome Episodes Requiring ICU Admission. <i>Critical Care Medicine</i> , 2017, 45, 1216-1223.	0.9	56
201	Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. <i>American Journal of Hematology</i> , 2018, 93, 424-429.	4.1	56
202	Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. <i>Clinical and Experimental Immunology</i> , 2013, 171, 186-194.	2.6	55
203	Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. <i>Arthritis and Rheumatism</i> , 2007, 56, 3420-3432.	6.7	54
204	Th1 and Th17 balance in inflammatory myopathies: Interaction with dendritic cells and possible link with response to high-dose immunoglobulins. <i>Cytokine</i> , 2009, 46, 297-301.	3.2	54
205	Phenotype-Haplotype Correlation of <i>IRF5</i> in Systemic Sclerosis: Role of 2 Haplotypes in Disease Severity. <i>Journal of Rheumatology</i> , 2010, 37, 987-992.	2.0	54
206	Expert Agreement on EULAR/EUSTAR Recommendations for the Management of Systemic Sclerosis: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 1326-1328.	2.0	54
207	Systemic Vasculitis During the Course of Systemic Sclerosis. <i>Medicine (United States)</i> , 2013, 92, 1-9.	1.0	54
208	Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. <i>Lupus Science and Medicine</i> , 2014, 1, e000027.	2.7	54
209	Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. <i>Rheumatology</i> , 2010, 49, 940-944.	1.9	53
210	Intravenous Immunoglobulins Improve Survival in Monoclonal Gammopathy-Associated Systemic Capillary-Leak Syndrome. <i>American Journal of Medicine</i> , 2017, 130, 1219.e19-1219.e27.	1.5	53
211	Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. <i>Lupus</i> , 2017, 26, 163-169.	1.6	53
212	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	1.9	53
213	Tocilizumab: Therapy and safety management. <i>Joint Bone Spine</i> , 2010, 77, S3-S100.	1.6	52
214	ANCA-associated vasculitis in patients with primary Sjögren's syndrome: Detailed analysis of 7 new cases and systematic literature review. <i>Autoimmunity Reviews</i> , 2015, 14, 742-750.	5.8	52
215	Personalized Physical Therapy Versus Usual Care for Patients With Systemic Sclerosis: A Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2017, 69, 1050-1059.	3.4	52
216	Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies. <i>Rheumatology</i> , 2010, 49, 1049-1055.	1.9	51

#	ARTICLE	IF	CITATIONS
217	Study of Anti-Müllerian Hormone and Its Relation to the Subsequent Probability of Pregnancy in 112 Patients With Systemic Lupus Erythematosus, Exposed or Not to Cyclophosphamide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3785-3792.	3.6	51
218	Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients. <i>Clinical Immunology</i> , 2018, 197, 54-59.	3.2	51
219	Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome. <i>Arthritis Research and Therapy</i> , 2013, 15, R149.	3.5	50
220	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.9	50
221	Association of a <i>KCNA5</i> gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. <i>Arthritis and Rheumatism</i> , 2010, 62, 3093-3100.	6.7	49
222	Association of the <i>CD226</i> Ser ³⁰⁷ variant with systemic sclerosis: Evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. <i>Arthritis and Rheumatism</i> , 2011, 63, 1097-1105.	6.7	49
223	Abatacept therapy and safety management. <i>Joint Bone Spine</i> , 2012, 79, 3-84.	1.6	49
224	Long-term outcome in idiopathic granulomatous mastitis: a western multicentre study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 433-441.	0.5	49
225	In Antisynthetase Syndrome, ACPA Are Associated With Severe and Erosive Arthritis. <i>Medicine (United States)</i> , 2015, 94, e784314.	1.0	49
226	Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. <i>Rheumatology</i> , 2015, 54, 1699-1708.	1.9	49
227	Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 1420-1430.	1.6	49
228	Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases. <i>Autoimmunity Reviews</i> , 2016, 15, 281-286.	5.8	49
229	Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. <i>Autoimmunity Reviews</i> , 2017, 16, 377-384.	5.8	49
230	Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2370-2379.	5.6	49
231	Immunological profiles determine neurological involvement in Sjögren's syndrome. <i>European Journal of Internal Medicine</i> , 2014, 25, 177-181.	2.2	48
232	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1074-1082.	4.7	48
233	Myocarditis in Patients With Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e798.	1.0	47
234	Reliability of histopathological salivary gland biopsy assessment in Sjögren's syndrome: a multicentre cohort study. <i>Rheumatology</i> , 2015, 54, 1056-1064.	1.9	47

#	ARTICLE	IF	CITATIONS
235	Cogan syndrome: Characteristics, outcome and treatment in a French nationwide retrospective study and literature review. <i>Autoimmunity Reviews</i> , 2017, 16, 1219-1223.	5.8	47
236	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. <i>PLoS ONE</i> , 2018, 13, e0197112.	2.5	47
237	Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study. <i>Journal of Hepatology</i> , 2010, 53, 1006-1012.	3.7	46
238	Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies. <i>European Respiratory Journal</i> , 2011, 37, 714-717.	6.7	46
239	Independent replication establishes the CD247 gene as a genetic systemic sclerosis susceptibility factor. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1695-1696.	0.9	46
240	C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: Results from a large french cohort and meta-analysis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2091-2096.	6.7	45
241	Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30 Suppl 1, i104-12.	0.7	45
242	Exclusion of Patients with a Severe T-Cell Defect Improves the Definition of Common Variable Immunodeficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 1147-1157.	3.8	45
243	Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Disease-related Interstitial Lung Diseases. <i>Journal of Rheumatology</i> , 2014, 41, 792-798.	2.0	43
244	High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sjögren's Syndrome: Data from the TEARS Randomized Trial. <i>PLoS ONE</i> , 2016, 11, e0162787.	2.5	43
245	Efficacy of Anti-TNF α in Severe and Refractory Neuro-Behcet Disease. <i>Medicine (United States)</i> , 2016, 95, e3550.	1.0	43
246	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. <i>Autoimmunity Reviews</i> , 2020, 19, 102452.	5.8	43
247	The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. <i>European Respiratory Journal</i> , 2011, 37, 1503-1513.	6.7	42
248	Gastrointestinal mucosal abnormalities using videocapsule endoscopy in systemic sclerosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 189-199.	3.7	42
249	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. <i>Presse Medicale</i> , 2014, 43, e345-e363.	1.9	42
250	Patients' views and needs about systemic sclerosis and its management: a qualitative interview study. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 230.	1.9	42
251	Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. <i>Arthritis Research and Therapy</i> , 2012, 14, R37.	3.5	41
252	Identification of NF- κ B and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 71.	3.5	41

#	ARTICLE	IF	CITATIONS
253	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	5.6	41
254	Pulmonary arterial hypertension in idiopathic inflammatory myopathies. <i>Medicine (United States)</i> , 2016, 95, e4911.	1.0	40
255	Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 780-783.	0.9	40
256	Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry. <i>Autoimmunity Reviews</i> , 2018, 17, 653-659.	5.8	40
257	Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. <i>Clinical Rheumatology</i> , 2004, 23, 516-522.	2.2	39
258	<i>Pneumocystis jirovecii</i> colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. <i>Rheumatology</i> , 2011, 50, 569-577.	1.9	39
259	Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease?. <i>Rheumatology</i> , 2019, 58, 1163-1167.	1.9	39
260	French recommendations for the management of systemic necrotizing vasculitides (polyarteritis) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf 50 4</i>	2.7	39
261	Abatacept therapy and safety management. <i>Joint Bone Spine</i> , 2009, 76, S3-S55.	1.6	38
262	A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome. <i>Rheumatology</i> , 2017, 56, kew376.	1.9	38
263	Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). <i>Current Rheumatology Reports</i> , 2016, 18, 10.	4.7	38
264	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	3.8	38
265	Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients. <i>Rheumatology</i> , 2015, 54, 927-932.	1.9	37
266	AA amyloidosis treated with tocilizumab: case series and updated literature review. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2015, 22, 84-92.	3.0	37
267	CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. <i>Haematologica</i> , 2015, 100, 1086-95.	3.5	37
268	Role of B cells in the pathogenesis of systemic sclerosis. <i>Revue De Medecine Interne</i> , 2017, 38, 113-124.	1.0	37
269	Incidence, risk factors, and mortality of neonatal and late-onset dilated cardiomyopathy associated with cardiac neonatal lupus. <i>International Journal of Cardiology</i> , 2017, 248, 263-269.	1.7	37
270	French recommendations for the management of systemic sclerosis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 322.	2.7	37

#	ARTICLE	IF	CITATIONS
271	Effect of Iterative Reconstruction on the Detection of Systemic Sclerosis-related Interstitial Lung Disease: Clinical Experience in 55 Patients. <i>Radiology</i> , 2016, 279, 297-305.	7.3	36
272	Kidney transplantation in patients with Fabry disease. <i>Transplant International</i> , 2009, 22, 475-481.	1.6	35
273	Independent Replication and Metaanalysis of Association Studies Establish TNFSF4 as a Susceptibility Gene Preferentially Associated with the Subset of Anticentromere-positive Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 997-1003.	2.0	35
274	Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. <i>Clinical Rheumatology</i> , 2014, 33, 799-805.	2.2	35
275	The Spectrum of Renal Involvement in Patients With Inflammatory Myopathies. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT/Overlo</i>	1.0	35
276	Systemic lupus erythematosus in Native sub-Saharan Africans: A systematic review and meta-analysis. <i>Journal of Autoimmunity</i> , 2020, 106, 102348.	6.5	35
277	Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. <i>Autoimmunity Reviews</i> , 2014, 13, 974-980.	5.8	34
278	Sjögren's syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000789.	3.8	34
279	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , 2021, 60, 5028-5041.	1.9	34
280	Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. <i>European Respiratory Review</i> , 2010, 19, 314-320.	7.1	33
281	Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1034-1041.	0.9	33
282	An international Survey on non-invasive techniques to assess the microcirculation in patients with Raynaud's phenomenon (SUNSHINE survey). <i>Rheumatology International</i> , 2017, 37, 1879-1890.	3.0	33
283	The IgG2 Isotype of Anti-Transcription Intermediary Factor 1 β Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1360-1370.	5.6	33
284	The complexity of managing systemic sclerosis: screening and diagnosis. <i>Rheumatology</i> , 2006, 48, iii8-iii13.	1.9	32
285	Male microchimerism and HLA compatibility in French women with scleroderma: a different profile in limited and diffuse subset. <i>Rheumatology</i> , 2009, 48, 363-366.	1.9	32
286	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
287	Prevalence of primary immunodeficiencies in France is underestimated. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1731-1733.	2.9	32
288	A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 54.	2.7	32

#	ARTICLE	IF	CITATIONS
289	Defects in the CD19 complex predispose to glomerulonephritis, as well as IgG1 subclass deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 538-541.e5.	2.9	31
290	Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 364-368.	1.3	31
291	Effect of In Vitro and In Vivo Anakinra on Cytokines Production in Schnitzler Syndrome. <i>PLoS ONE</i> , 2013, 8, e59327.	2.5	31
292	Postrehabilitation Functional Improvements in Patients With Inflammatory Myopathies: The Results of a Randomized Controlled Trial. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, 227-234.	0.9	31
293	Comparison of the Farr radioimmunoassay, 3 commercial enzyme immunoassays and <i>Crithidia luciliae</i> immunofluorescence test for diagnosis and activity assessment of systemic lupus erythematosus. <i>Clinica Chimica Acta</i> , 2010, 411, 959-964.	1.1	30
294	Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients. <i>Lupus</i> , 2011, 20, 861-865.	1.6	30
295	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <scp>SLE</scp>: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 374-382.	4.7	30
296	Mixed connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000783.	3.8	30
297	Rituximab (MabThera) therapy and safety management. Clinical tool guide developed by the Rheumatic Diseases & Inflammation Group (Club Rhumatismes et Inflammation, CRI) of the French Society for Rheumatology (Société Française de Rhumatologie, SFR). <i>Joint Bone Spine</i> , 2008, 75, S2-S99.	1.6	29
298	Association of hypoxia-inducible factor 1A (<i>HIF1A</i>) gene polymorphisms with systemic sclerosis in a French European Caucasian population. <i>Scandinavian Journal of Rheumatology</i> , 2009, 38, 291-294.	1.1	29
299	Does the route of immunoglobulin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages". <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 83.	2.7	28
300	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000786.	3.8	28
301	Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. <i>Rheumatology</i> , 2019, 58, 1565-1573.	1.9	28
302	Association Between a CTGF Gene Polymorphism and Systemic Sclerosis in a French Population. <i>Journal of Rheumatology</i> , 2010, 37, 351-358.	2.0	27
303	Parental Consanguinity is Associated with a Severe Phenotype in Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2012, 32, 98-105.	3.8	27
304	In silico validation of the Autoinflammatory Disease Damage Index. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1599-1605.	0.9	27
305	Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. <i>European Respiratory Review</i> , 2011, 20, 270-276.	7.1	26
306	Malignant Retroperitoneal Fibrosis. <i>Medicine (United States)</i> , 2012, 91, 242-250.	1.0	26

#	ARTICLE	IF	CITATIONS
307	Brief Report: A Regulatory Variant in <i>CCR6</i> Is Associated With Susceptibility to Antitopoisomerase-Positive Systemic Sclerosis. <i>Arthritis and Rheumatism</i> , 2013, 65, 3202-3208.	6.7	26
308	DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. <i>Lupus</i> , 2015, 24, 648-649.	1.6	26
309	Challenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease. <i>Clinical Genetics</i> , 2022, 101, 390-402.	2.0	26
310	Gaucher disease and monoclonal gammopathy: A report of 17 cases and impact of therapy. <i>Blood Cells, Molecules, and Diseases</i> , 2009, 43, 138-139.	1.4	25
311	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. <i>Rheumatology</i> , 2015, 54, 1262-1269.	1.9	25
312	Impairment of quality of life in patients with antiphospholipid syndrome. <i>Lupus</i> , 2015, 24, 1161-1168.	1.6	25
313	Diagnosis of primary antibody and complement deficiencies in young adults after a first invasive bacterial infection. <i>Clinical Microbiology and Infection</i> , 2017, 23, 576.e1-576.e5.	6.0	25
314	Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 1679-1686.	1.6	25
315	Serious Infectious Events and Immunoglobulin Replacement Therapy in Patients With Autoimmune Disease Receiving Rituximab: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 727-737.	5.8	25
316	Musculoskeletal Symptoms in Patients With Cryopyrin-Associated Periodic Syndromes: A Large Database Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 3027-3036.	5.6	24
317	A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR- γ) gene and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 128.	3.5	24
318	Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency. <i>Medicine (United States)</i> , 2016, 95, e3027.	1.0	24
319	Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. <i>Rheumatology</i> , 2020, 59, 3807-3816.	1.9	24
320	Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1420-1427.	0.9	24
321	Subluxing arthropathy: an unusual manifestation of the antisynthetase syndrome. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 152-153.	0.9	23
322	Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review. <i>Journal of Rheumatology</i> , 2018, 45, 425-429.	2.0	23
323	Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study. <i>RMD Open</i> , 2020, 6, e001340.	3.8	23
324	Association Study of <i>ITGAM</i> , <i>ITGAX</i> , and <i>CD58</i> Autoimmune Risk Loci in Systemic Sclerosis: Results from 2 Large European Caucasian Cohorts. <i>Journal of Rheumatology</i> , 2011, 38, 1033-1038.	2.0	22

#	ARTICLE	IF	CITATIONS
325	Factors associated with the 6-minute walk distance in patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2017, 19, 279.	3.5	22
326	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 339-346.	3.4	22
327	IgG4-related diseases: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000787.	3.8	21
328	Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS. <i>Rheumatology</i> , 2021, 60, 675-681.	1.9	21
329	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. <i>Journal of Psychosomatic Research</i> , 2020, 135, 110132.	2.6	21
330	Pulmonary hypertension subtypes associated with hereditary haemorrhagic telangiectasia: Haemodynamic profiles and survival probability. <i>PLoS ONE</i> , 2017, 12, e0184227.	2.5	21
331	B-cell and T-cell quantification in minor salivary glands in primary Sjögren's syndrome: development and validation of a pixel-based digital procedure. <i>Arthritis Research and Therapy</i> , 2016, 18, 21.	3.5	20
332	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. <i>Arthritis Research and Therapy</i> , 2020, 22, 257.	3.5	20
333	Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2020, 22, 30.	3.5	20
334	¹⁸ F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. <i>Arthritis Research and Therapy</i> , 2021, 23, 76.	3.5	20
335	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	1.9	20
336	Comparing HLA Shared Epitopes in French Caucasian Patients with Scleroderma. <i>PLoS ONE</i> , 2012, 7, e36870.	2.5	19
337	Pulmonary perfusion scintigraphy: A tool to detect the presence of pulmonary artery involvement in Takayasu's arteritis. <i>Presse Medicale</i> , 2012, 41, e37-e42.	1.9	19
338	Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?. <i>PLoS ONE</i> , 2015, 10, e0133907.	2.5	19
339	Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease. <i>Lupus</i> , 2016, 25, 1440-1447.	1.6	19
340	Special considerations in pregnant systemic sclerosis patients. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1161-1173.	3.0	19
341	Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 127.	2.7	19
342	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000784.	3.8	19

#	ARTICLE	IF	CITATIONS
343	Vaccination in adults with auto-immune disease and/or drug related immune deficiency: Results of the GEVACCIM Delphi survey. <i>Vaccine</i> , 2009, 27, 1523-1529.	3.8	18
344	TGF β 2 receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1900-1903.	0.9	18
345	Distinctive Patterns of Transthyretin Amyloid in Salivary Tissue. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1035-1044.	3.7	18
346	Patient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual care. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 694-700.	3.4	18
347	Rituximab and Cyclophosphamide in Antisynthetase Syndrome-related Interstitial Lung Disease: An Observational Retrospective Study. <i>Journal of Rheumatology</i> , 2020, 47, 1678-1686.	2.0	18
348	Myocardial involvement in systemic capillary leak syndrome: first demonstration by pathologic findings. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012, 1, 248-252.	1.0	17
349	Prevalence, characteristics and prognostic significance of anemia in daily practice. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 345-354.	0.5	17
350	Understanding remission in real-world lupus patients across five European countries. <i>Lupus</i> , 2016, 25, 505-512.	1.6	17
351	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2209-2221.	5.6	17
352	Validation of the Social Appearance Anxiety Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1557-1562.	3.4	17
353	Prevalence and Clinical Associations of Antiphospholipid Antibodies in Systemic Sclerosis: New Data From a French Cross-Sectional Study, Systematic Review, and Meta-Analysis. <i>Frontiers in Immunology</i> , 2018, 9, 2457.	4.8	17
354	The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder. <i>Lancet Rheumatology</i> , The, 2019, 1, e257-e264.	3.9	17
355	Characteristics and management of giant cell arteritis in France: a study based on national health insurance claims data. <i>Rheumatology</i> , 2020, 59, 120-128.	1.9	17
356	Vertebral fractures in Gaucher disease type I: data from the French "Observatoire" on Gaucher disease (FROG). <i>Osteoporosis International</i> , 2011, 22, 1255-1261.	3.1	16
357	Anti-synthetase syndrome positive for anti-isoleucyl-tRNA synthetase antibodies: an unusual case overlapping with systemic sclerosis and Sjogren's syndrome. <i>Rheumatology</i> , 2011, 50, 1175-1176.	1.9	16
358	Efficacy and safety of a new oral saliva equivalent in the management of xerostomia: a national, multicenter, randomized study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015, 119, 301-309.	0.4	16
359	N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. <i>International Journal of Cardiology</i> , 2016, 223, 385-389.	1.7	16
360	A prospective study of the 6-minute walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1457-1465.	0.9	16

#	ARTICLE	IF	CITATIONS
361	Systemic capillary leak syndrome and autoimmune diseases: A case series. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 509-512.	3.4	16
362	Aortic aneurysm in MAGIC syndrome successfully managed with combined anti-TNF- α and stent grafting. <i>Rheumatology</i> , 2009, 48, 1169-1170.	1.9	15
363	Angiotensin-Converting Enzyme Gene Does Not Contribute to Genetic Susceptibility to Systemic Sclerosis in European Caucasians. <i>Journal of Rheumatology</i> , 2009, 36, 337-340.	2.0	15
364	Graft-versus-host disease-related polymyositis. <i>Clinical Rheumatology</i> , 2010, 29, 431-433.	2.2	15
365	Multidimensional analysis of clinical symptoms in patients with Fabry's disease. <i>International Journal of Clinical Practice</i> , 2013, 67, 120-127.	1.7	15
366	Specific Polysaccharide Antibody Deficiency Revealed by Severe Bacterial Infections in Adulthood: A Report on 11 Cases. <i>Clinical Infectious Diseases</i> , 2017, 65, 328-331.	5.8	15
367	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	5.6	15
368	Relevance of Partitioning DLCO to Detect Pulmonary Hypertension in Systemic Sclerosis. <i>PLoS ONE</i> , 2013, 8, e78001.	2.5	15
369	Effective immune restoration after immunosuppressant discontinuation in a lupus patient presenting progressive multifocal leukoencephalopathy. <i>Journal of the Neurological Sciences</i> , 2009, 287, 246-249.	0.6	14
370	High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. <i>International Journal of Neuroscience</i> , 2017, 127, 516-523.	1.6	14
371	Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study. <i>Arthritis Care and Research</i> , 2017, 69, 903-911.	3.4	14
372	B Cell Homeostasis and Functional Properties Are Altered in an Hypochlorous Acid-Induced Murine Model of Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2017, 8, 53.	4.8	14
373	Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study. <i>Lupus</i> , 2018, 27, 357-364.	1.6	14
374	Whole-Body Distribution and Clinical Association of Telangiectases in Systemic Sclerosis. <i>JAMA Dermatology</i> , 2018, 154, 796.	4.1	14
375	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. <i>Rheumatology</i> , 2020, 59, 2016-2023.	1.9	14
376	Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective study. <i>Autoimmunity Reviews</i> , 2020, 19, 102634.	5.8	14
377	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	2.5	13
378	Survival Improved in Patients Aged \geq 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. <i>Chest</i> , 2020, 157, 945-954.	0.8	13

#	ARTICLE	IF	CITATIONS
379	Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. <i>PLoS ONE</i> , 2016, 11, e0151696.	2.5	13
380	Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 398-402.	1.1	12
381	Two-year follow-up after endobronchial coil treatment in emphysema: results from the REVOLENS study. <i>European Respiratory Journal</i> , 2017, 50, 1701740.	6.7	12
382	S100A12 and S100A8/9 proteins are biomarkers of articular disease activity in Blau syndrome. <i>Rheumatology</i> , 2018, 57, 1299-1304.	1.9	12
383	Thrombocytopenia in primary antiphospholipid syndrome, a marker of high-risk patients?. <i>European Journal of Internal Medicine</i> , 2020, 74, 106-107.	2.2	12
384	Extended myositis-specific and -associated antibodies profile in systemic sclerosis: A cross-sectional study. <i>Joint Bone Spine</i> , 2021, 88, 105048.	1.6	12
385	Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic). <i>Arthritis Research and Therapy</i> , 2021, 23, 70.	3.5	12
386	Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS). <i>Joint Bone Spine</i> , 2021, 88, 105162.	1.6	12
387	Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FiRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteria. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 35-42.	0.8	12
388	Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: Description and prognosis factors. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1406-1413.	3.4	11
389	Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1123-1125.	0.9	11
390	Association of Metalloproteinase Gene Polymorphisms with Systemic Sclerosis in the European Caucasian Population. <i>Journal of Rheumatology</i> , 2010, 37, 599-602.	2.0	10
391	Association Study of Serotonin Transporter Gene (SLC6A4) in Systemic Sclerosis in European Caucasian Populations. <i>Journal of Rheumatology</i> , 2010, 37, 1164-1167.	2.0	10
392	Coexistence of rheumatoid arthritis and TEMPI syndrome: New insight in microangiogenic-related diseases. <i>Joint Bone Spine</i> , 2016, 83, 587-588.	1.6	10
393	Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody-associated Vasculitis-related Bronchiectasis: Data from 61 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 1522-1531.	2.0	10
394	Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 436-441.	3.4	10
395	Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases. <i>European Journal of Internal Medicine</i> , 2021, 91, 45-52.	2.2	10
396	Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study). <i>Frontiers in Medicine</i> , 2021, 8, 732934.	2.6	10

#	ARTICLE	IF	CITATIONS
397	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. <i>Rheumatology</i> , 2022, 61, 4384-4396.	1.9	10
398	Interstitial pneumonia with autoimmune features: Evaluation of connective tissue disease incidence during follow-up. <i>European Journal of Internal Medicine</i> , 2022, 97, 62-68.	2.2	10
399	Diluted Russell viper-venom time improves identification of antiphospholipid syndrome in a lupus anticoagulant-positive patient population. <i>Thrombosis and Haemostasis</i> , 2009, 101, 577-581.	3.4	9
400	Systemic sclerosis and prevalence of monoclonal immunoglobulin. <i>Autoimmunity Reviews</i> , 2014, 13, 1189-1194.	5.8	9
401	Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. <i>European Respiratory Journal</i> , 2017, 49, 1700178.	6.7	9
402	Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients. <i>Journal of Clinical Immunology</i> , 2018, 38, 503-512.	3.8	9
403	Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. <i>Current Research in Translational Medicine</i> , 2018, 66, 83-86.	1.8	9
404	Positive Impact of Expert Reference Center Validation on Performance of Next-Generation Sequencing for Genetic Diagnosis of Autoinflammatory Diseases. <i>Journal of Clinical Medicine</i> , 2019, 8, 1729.	2.4	9
405	Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. <i>Lancet Rheumatology</i> , The, 2021, 3, e844-e854.	3.9	9
406	Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. <i>RMD Open</i> , 2022, 8, e002160.	3.8	9
407	Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. <i>Rheumatology</i> , 2014, 53, 639-643.	1.9	8
408	Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 759-766.	3.4	8
409	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1646-1652.	3.4	8
410	Adherence to hydroxychloroquine in patients with systemic lupus: Contrasting results and weak correlation between assessment tools. <i>Joint Bone Spine</i> , 2020, 87, 603-610.	1.6	8
411	Epidemiology of Idiopathic Inflammatory Myopathies in Africa. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e552-e562.	0.9	8
412	Localized versus systemic granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. <i>Rheumatology</i> , 2022, 61, 2464-2471.	1.9	8
413	Practical management of patients on hydroxychloroquine. <i>Joint Bone Spine</i> , 2021, 88, 105316.	1.6	8
414	Subcutaneous Immunoglobulin Therapy Prevents Systemic Capillary Leak Syndrome Attack. <i>American Journal of Medicine</i> , 2016, 129, e77-e78.	1.5	7

#	ARTICLE	IF	CITATIONS
415	Familial and syndromic lupus share the same phenotype as other early-onset forms of lupus. <i>Joint Bone Spine</i> , 2017, 84, 589-593.	1.6	7
416	Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study). <i>Respiratory Research</i> , 2018, 19, 84.	3.6	7
417	Campylobacter infection in adult patients with primary antibody deficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1038-1041.e4.	3.8	7
418	Assessment of T-cell polarization on the basis of surface marker expression: Diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1110-1114.e2.	3.8	7
419	Impact of Three Different Algorithms for the Screening of SSc-PAH and Comparison with the Decisions of a Multidisciplinary Team. <i>Diagnostics</i> , 2021, 11, 1738.	2.6	7
420	An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: A study of a national retrospective cohort of 1375 patients over 10 years. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 2116-2125.	2.9	7
421	Soluble HLA-G Expression Inversely Correlates With Fetal Microchimerism Levels in Peripheral Blood From Women With Scleroderma. <i>Frontiers in Immunology</i> , 2018, 9, 1685.	4.8	6
422	Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN ReCONNET survey. <i>RMD Open</i> , 2020, 6, e001344.	3.8	6
423	The consequences of COVID-19 pandemic on patients with monoclonal gammopathy-associated systemic capillary leak syndrome (Clarkson disease). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 626-629.	3.8	6
424	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. <i>Rheumatology</i> , 2022, 61, 4035-4046.	1.9	6
425	Dyslipidemia is insufficiently treated in antiphospholipid syndrome patients. <i>Lupus</i> , 2022, 31, 1379-1384.	1.6	6
426	Simple gene signature to assess murine fibroblast polarization. <i>Scientific Reports</i> , 2022, 12, .	3.3	6
427	Biologic targeted therapies in pediatric rheumatology. <i>Joint Bone Spine</i> , 2014, 81, 2-48.	1.6	5
428	Exploring patient education unmet needs for rare and complex connective tissue and musculoskeletal diseases: A survey of health care providers' and patients' expectations in Europe. <i>Chronic Illness</i> , 2020, , 174239532096861.	1.5	5
429	Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 49-56.	1.7	5
430	Epidemiology, Mortality and Healthcare Resource Utilization Associated With Systemic Sclerosis-Associated Interstitial Lung Disease in France. <i>Frontiers in Medicine</i> , 2021, 8, 699532.	2.6	5
431	Concomitant fibromyalgia in primary Sjögren's syndrome in the French ASSESS cohort: comparison of the ACR 1990 and ACR 2016 criteria, FIRST questionnaire and physician's opinion. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 140-145.	0.8	5
432	Inaugural raynaud's phenomenon is associated with a multisystemic involvement during follow-up in primary sjögren's syndrome: A report of 162 patients. <i>International Journal of Angiology</i> , 2004, 13, 71-74.	0.6	4

#	ARTICLE	IF	CITATIONS
433	Maladie de Takayasu: caractéristiques cliniques, prise en charge diagnostique, traitement et pronostic. <i>Medecine Nucleaire</i> , 2009, 33, 512-517.	0.2	4
434	Beneficial effect of intravenous immunoglobulins on systemic capillary leak syndrome in patients with monoclonal gammopathy. <i>Critical Care Medicine</i> , 2009, 37, 795.	0.9	4
435	Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating "not applicable" responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. <i>BMJ Open</i> , 2018, 8, e018641.	1.9	4
436	Outcomes of pregnancy and associated factors in sub-Saharan African women with systemic lupus erythematosus: a scoping review. <i>Lupus Science and Medicine</i> , 2020, 7, e000400.	2.7	4
437	Elevated Plasma Fibrinogen in Clinically Asymptomatic Unicentric Castleman's Disease: A Case Report. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2014, 54, 85-88.	0.8	4
438	Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study. <i>BioMed Research International</i> , 2018, 2018, 1-10.	1.9	3
439	Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis After Treatment With Siltuximab. <i>Journal of Clinical Rheumatology</i> , 2019, 25, e40-e42.	0.9	3
440	Epidemiology of Sjögren Syndrome in Africa. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e240-e244.	0.9	3
441	Systemic Pulmonary Events Associated with Myelodysplastic Syndromes: A Retrospective Multicentre Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1162.	2.4	3
442	Correspondence in reference to the previously published Epub manuscript: immune thrombocytopenic purpura after SARS-CoV-2 vaccine. <i>British Journal of Haematology</i> , 2021, 194, e93-e95.	2.5	3
443	Health Outcomes of 215 Mothers of Children With Autoimmune Congenital Heart Block: Analysis of the French Neonatal Lupus Syndrome Registry. <i>Journal of Rheumatology</i> , 2022, 49, 1124-1130.	2.0	3
444	Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort. <i>Rheumatology</i> , 0, , .	1.9	3
445	Could the Cochin risk prediction score be applied in daily practice to predict pulmonary hypertension in systemic sclerosis? Comment on the article by Meune et al. <i>Arthritis and Rheumatism</i> , 2012, 64, 2051-2052.	6.7	2
446	Association study of CRP gene in systemic sclerosis in European Caucasian population. <i>Rheumatology International</i> , 2014, 34, 389-392.	3.0	2
447	Disease severity of proliferative lupus nephritis in Maghrebians. <i>Lupus</i> , 2018, 27, 1387-1392.	1.6	2
448	Imaging in Systemic Sclerosis: Make "US" Great Again? Comment on the Article by Santiago et al. <i>Arthritis Care and Research</i> , 2019, 71, 694-695.	3.4	2
449	Comment on: Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease? Reply. <i>Rheumatology</i> , 2019, 58, 1312-1313.	1.9	2
450	Epidemiological data on systemic lupus erythematosus in native sub-Saharan Africans. <i>Data in Brief</i> , 2020, 28, 104909.	1.0	2

#	ARTICLE	IF	CITATIONS
451	Consideration of coping strategies for patients suffering from systemic lupus erythematosus: reflection for a personalised practice of patient education. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 705-712.	0.8	2
452	Protein-losing Enteropathy as a Complication and/or Differential Diagnosis of Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2022, 42, 1461-1472.	3.8	2
453	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. <i>Chest</i> , 2010, 138, 462-463.	0.8	1
454	Osteolytic Lesion with Thick Sclerotic Walls and Demyelinating Polyneuropathy. <i>Journal of Rheumatology</i> , 2012, 39, 2175-2176.	2.0	1
455	Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus. <i>PLoS ONE</i> , 2016, 11, e0160283.	2.5	1
456	Reply to Gilchrist et al. and to Musher. <i>Clinical Infectious Diseases</i> , 2018, 66, 637-638.	5.8	1
457	OPO239â€¦PROGRESSIVE LUNG FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN THE EUSTAR DATABASE. , 2019, , .		1
458	FRI0283â€¦PRESENTATION AND MANAGEMENT OF GIANT CELL ARTERITIS IN A REAL-WORLD SETTING (ARTEMIS) Tj ETQq0 Q 0 rgBT /O		
459	A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 43-48.	0.8	1
460	An exceptional minute tumour incidentally found in a renal biopsy. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1436-1438.	0.7	0
461	Clinical Assessment of Pulmonary Hypertension. , 2012, , 429-435.		0
462	Recurrent limb and facial oedema with R92Q mutation: A non-febrile late-onset tumour necrosis factor receptor-associated periodic syndrome (TRAPS)?. <i>Presse Medicale</i> , 2013, 42, 905-906.	1.9	0
463	FRI0325â€¦IDENTIFYING SYSTEMIC SCLEROSIS PATIENTS AT RISK OF PROGRESSIVE LUNG FIBROSIS â€œ A EUSTAR DATABASE ANALYSIS. , 2019, , .		0
464	Ã‰tude transversale des profils anticorps spÃ©cifiques et associÃ©s aux myosites dans la sclÃ©rodermie systÃ©mique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 284-290.	0.0	0
465	Observance du traitement par hydroxychloroquine dans le lupus systÃ©mique: rÃ©sultats contrastÃ©s et faible corrÃ©lation entre les outils d'Ã©valuation. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 369-376.	0.0	0
466	Low hormone levels during an attack of systemic capillary leak syndrome normalizing after treatment. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.7	0
467	Passages in culture and stimulation conditions influence protein expression of primary fibroblasts. <i>Proteomics</i> , 2021, , 2100116.	2.2	0